HC Wainwright Rates Genmab A (GMAB) buy, $38 Price Target

HC Wainwright maintains its buy rating on GMAB with a $38 target, a 46.92% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 7:01 AM EDT · Updated Jun 25, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Genmab A ($GMAB) "buy" with a $38 price target on June 23, 2026.

Since the rating, $GMAB is up 5.9% after 1 week, up 12.4% after 1 month and up 42.6% to date (from the $25.94 close on Jun 23, 2026).

GMAB Genmab A

$37 +16.28% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on GMAB with a $38 price target on June 23, 2026.
HC Wainwright's $38 price target implies 46.92% upside from Genmab A's ($GMAB) current $25.86 share price.
GMAB shares were trading around $25.61 on Tuesday, with various institutional investors adjusting their stakes.
Insider Judith Klimovsky sold shares on June 17, 2025, while analysts maintain positive outlooks.

Get $GMAB trade alerts by text

We text you when insiders, Congress or big funds trade $GMAB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Genmab A alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating for GMAB, setting a price target of $38 as of June 23, 2026. Analyst Raghuram Selvaraju continues to see potential in the stock, maintaining the positive outlook.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +53.56% hypothetical

All-time return +155.65% S&P 500 +28.65%

vs. S&P 500 +127% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in GMAB

Several institutional investors have recently adjusted their positions in GMAB. Orbis Allan Gray Ltd reduced its holdings by 1,492,884 shares, ending with 12,925,578 shares valued at approximately $346.8 million, marking a 10.4% decrease. AllianceBernstein L.P. also trimmed its stake by 1,319,945 shares, now holding 9,557,149 shares worth about $294.4 million, a 12.1% reduction. On the other hand, Paradigm Biocapital Advisors LP increased its holdings by 928,002 shares, bringing its total to 7,967,836 shares valued at $213.8 million, a 13.2% increase. Arrowstreet Capital slightly decreased its position, while Renaissance Technologies LLC notably increased its stake by 921,700 shares, a 26.4% jump.

Genmab A Stock Down 25.5%

On Tuesday, GMAB shares were trading near $25.61. The stock has seen various institutional adjustments and continues to be a point of focus for analysts and investors alike.

12-month forecast

$GMAB price target

Genmab A daily closes and this analyst's $38 target. Not advice.

Insider Buying and Selling at Genmab A

Insider Judith Klimovsky sold 1,300 shares at an average price of $51.69 and another batch of 1,300 shares at $52.00 on June 17, 2025. Previously, on March 1, 2024, she sold 1,200 shares at $275.00, with one of these transactions being planned.

Analysts Set New Price Targets

On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on GMAB with a $38 price target. Earlier, on April 30, 2026, the firm maintained the same rating and target. Wolfe Research initiated coverage with a buy rating and a $32 target on March 27, 2026, while Wells Fargo also started coverage with a buy rating, setting a $40 target on March 2, 2026. The consensus among analysts remains positive, with a general buy recommendation and a mean target price reflecting optimism in GMAB's prospects.

About GMAB

GMAB is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary technology platforms to create novel treatments aimed at improving patient outcomes. Headquartered in Denmark, GMAB works on advancing its pipeline of products through various stages of clinical development.

Bottom Line

HC Wainwright's reiterated buy rating and $38 target for GMAB underscore continued confidence in the company's potential. Investors keep a close eye on GMAB due to its promising pipeline and the stock's dynamic trading activity. As always, it's important to remember that these analyst ratings are based on past data and projections, which may not necessarily predict future performance.